Study on Exosome Changes in Patients With Proliferative Diabetic Retinopathy
NCT06198543 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 60
Last updated 2024-01-10
Summary
Diabetic retinopathy is a common complication of diabetes and one of the leading causes of low vision and blindness in adults. In recent years, the prevalence of diabetes and the incidence of diabetic retinopathy have increased significantly in our country. Epidemiological studies show that the prevalence rate of diabetes in China is 12.8%, and the prevalence rate of DR in adult diabetic patients is 24.7%-37.5%, that is, there are about 3200-48 million DR patients in China, and the patients have a trend of younger people. DR has become a serious public health problem threatening people's lives and health.
At present, it is known that the pathogenesis of DR is related to hypoxia, oxidative stress, inflammation, abnormal expression of cytokines and gene methylation, but the specific pathogenesis has not been fully clarified. Due to the hidden early symptoms of DR, the lack of basic screening conditions in primary medical and health institutions, and the lack of awareness of DR by patients themselves, many DR patients have already appeared serious retinopathy when they seek medical treatment, resulting in irreversible visual function impairment. In addition, the current clinical treatment methods for DR mainly include retinal photocoagulation therapy, intraocular anti-VEGF drug injection and vitrectomy surgery, etc. These methods are aimed at relatively severe diabetic retinopathy, and there is no effective treatment method for early diabetic retinopathy that can prevent or slow down the occurrence and development of DR. Therefore, to further explore the pathogenesis of DR and develop new therapeutic methods has become an urgent problem.
Exosomes are extracellular vesicles secreted by living cells with a diameter of 40-150nm. With a bilayer lipid membrane structure, exosomes contain a variety of biomolecules such as lipids, proteins, nucleic acids, cytokines, and autoantigens, and are important mediators for the transmission of biological information between cells. Almost all cells can secrete exosomes, and exosomes from different cells have different functions. Exosomes transfer their contents to nearby or distant cells and participate in cell growth, angiogenesis, immune regulation and other processes. Previous studies have shown that exosomes secreted by various cells in the retina are present in the vitreous and aqueous humor of patients and play an important role in the pathogenesis of DR. At the same time, exosomes in the systemic circulation of diabetic patients can also reach the retina through the blood circulation, participate in the initiation process of DR And play an important role. At the same time, due to the double-layer lipid membrane structure, exosomes can also target the coated components to specific cells and tissues through biological barriers such as blood-brain and blood-eye, which is expected to become a highly efficient drug delivery route. Therefore, the role of exosomes in DR Treatment has also attracted much attention.
Conditions
Sponsors & Collaborators
-
Xuanwu Hospital, Beijing
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-01-31
- Primary Completion
- 2025-01-31
- Completion
- 2025-04-30
More Related Trials
-
A Study of the Safety and Efficacy of SK-0503 for Diabetic Macular Edema
NCT00308542 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Shanghai Beixinjing Diabetic Eyes Study
NCT03571217 ·Status: UNKNOWN
-
A Systematic Study of Retinal Structure and Function in Diabetic Macular Oedema
NCT02876393 ·Status: COMPLETED
-
Pars-plana Vitrectomy vs Panretinal Photocoagulation for Severe NPDR
NCT04103671 ·Status: RECRUITING ·Phase: NA
-
A Clinical Study Evaluating the Safety, Tolerability and Initial Efficacy of SKG0106 Intravitreal Injection in Diabetic Macular Edema (DME) Patients
NCT06237777 ·Status: RECRUITING ·Phase: PHASE1
-
Intranasal Delivery of Octreotide for Treatment of Diabetic Macular Edema
NCT06881888 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
A Multi-center Study to Evaluate Performance of an Automated Device for the Detection of Diabetic Retinopathy
NCT02963441 ·Status: COMPLETED
-
Study of Natural Course Progression of Diabetic Retinopathy
NCT06269419 ·Status: RECRUITING
-
Establishment and Validation of a Risk Prediction Model for Long-term Low Vision After Vitrectomy in PDR Patients
NCT05631054 ·Status: UNKNOWN
-
Laser and Antioxidant Treatment of Diabetic Macular Edema
NCT00055042 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of Conbercept for Diabetic Macular Edema Combined With Severe Non-proliferative Diabetic Retinopathy
NCT06305143 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Skin and Retina Microvascular Endothelial Function in Healthy, Insulin Resistant and Type 2 Diabetic Subjects
NCT01241370 ·Status: COMPLETED
-
Treatment of Diabetic Macular Edema (DME) With Anti-VEGF and Focal Laser
NCT03590444 ·Status: COMPLETED ·Phase: PHASE4
-
Study Investigating the Levels and Effects of Low-grade Inflammation in Diabetic Retinopathy of Type 1 Diabetes
NCT00880139 ·Status: TERMINATED
-
Study on Precision Treatment of Diabetic Retinopathy Macular Edema Guided by Real-time OCT During Operation
NCT05138029 ·Status: UNKNOWN ·Phase: PHASE3
-
Intravitreal Dexamethasone Implant for Refractory Diabetic Macular Edema:
NCT05847088 ·Status: COMPLETED
-
Longitudinal Natural History Study of Retinal Function in Eyes of Patients With Diabetes
NCT07270133 ·Status: NOT_YET_RECRUITING
-
25-Gauge Vitrectomy With Ranibizumab or Triamcinolone Acetonide on Proliferative Diabetic Retinopathy in China
NCT02328118 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Ranibizumab vs Dexamethasone Implant in Vitrectomized Eyes With Diabetic Macular Edema
NCT04089605 ·Status: COMPLETED ·Phase: PHASE4
-
Brolucizumab Efficacy and Safety Single-Arm Descriptive Trial in Patients With Persistent Diabetic Macular Edema
NCT06498050 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
OCT-angiography in Diabetic Patients
NCT02870803 ·Status: UNKNOWN
-
Restoration of Retinal Vascular Responses in Type 1 Diabetic Patients
NCT02099981 ·Status: COMPLETED ·Phase: PHASE1
-
Diabetic Macular Edema (DME) Treatment With Ranibizumab and Dexamethasone or Ranibizumab Only.
NCT04601675 ·Status: UNKNOWN ·Phase: NA
-
Effectiveness of Intravitreal Injection of Aflibercept 8 mg in Resistant Diabetic Macular Edema, Retinal Vein Occlusion and Myopic Choroidal Neovascularisation Patients
NCT06879301 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
A Trial on Ophthalmologist-delivered Health Education on Top of Routine Community Care
NCT04490941 ·Status: UNKNOWN ·Phase: NA